Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Current Deferred Revenue (2018 - 2024)

Dna X (SONM) has disclosed Current Deferred Revenue for 7 consecutive years, with $12000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Current Deferred Revenue changed N/A year-over-year to $12000.0, compared with a TTM value of $12000.0 through Jun 2024, changed N/A, and an annual FY2023 reading of $12000.0, down 61.29% over the prior year.
  • Current Deferred Revenue was $12000.0 for Q2 2024 at Dna X, roughly flat from $12000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $872000.0 in Q2 2021 and bottomed at $3000.0 in Q1 2023.
  • Average Current Deferred Revenue over 5 years is $166933.3, with a median of $31000.0 recorded in 2022.
  • The sharpest move saw Current Deferred Revenue crashed 98.28% in 2020, then surged 300.0% in 2024.
  • Year by year, Current Deferred Revenue stood at $5000.0 in 2020, then soared by 120.0% to $11000.0 in 2021, then soared by 181.82% to $31000.0 in 2022, then tumbled by 61.29% to $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024.
  • Business Quant data shows Current Deferred Revenue for SONM at $12000.0 in Q2 2024, $12000.0 in Q1 2024, and $12000.0 in Q4 2023.